

A North American company focused on providing gastroenterologists (“GIs”) with innovative products and services for the diagnosis and treatment of gastrointestinal diseases.

**CAPITAL STRUCTURE**

at April 30, 2017

Issued and OS Shares: **73.9** Million  
Fully Diluted Shares: **75.7** Million

**MARKET CAPITAL**

CDN\$**593.4** Million  
US\$**436.0** Million

**3-Month Average Daily Trading Volume**

TSX: 577,453 shares  
NYSE MKT: 208,609 shares

**FINANCIAL STRENGTH**

at March 31, 2017

**\$9.2** Million cash and cash equivalents

**\$22.0** Million available under Scotia debt facility at LIBOR plus 2.75%

**\$48.3** Million in debt

**GASTROENTEROLOGY FACTS**

- Routine colonoscopies for individuals +50 is the US standard of care for early detection of colon cancer
- +15 million endoscopic procedures are performed in the US annually
- Roughly 50% of endoscopic procedures are anesthesia-assisted
- Approximately 800-1,000 GI-specific Ambulatory Surgical Centres (“ASCs”)
- Approximately 10.4 million people suffer from hemorrhoids in the US\*

\*According to the National Institute of Diabetes & Digestive & Kidney Diseases

Our goal is to be the trusted partner for the GI community and the preeminent provider of GI anesthesia in the US.



**CRH ORegan System®**

Non-Surgical Hemorrhoid Treatment  
*Fast. Painless. Proven.*


**CRH Anesthesia**

Management

- Single-use, disposable banding system for hemorrhoid treatment
- Paradigm shift for GIs in the US
- Turnkey package includes training protocols, product, and operational + marketing expertise
- Utilized in all lower 48 US states
- Q1 2017 adjusted operating EBITDA margin: 63%
- Trained ~2,490 GIs in ~963 GI private practices (at March 31, 2017)

- Anesthesia services for upper and lower endoscopic procedures performed by GIs in Ambulatory Surgical Centers (“ASCs”)
- First transaction in December 2014; 10 more transactions completed since then for total investment of \$134.6 Million
- Q1 2017 adjusted operating EBITDA margin: 52%
- Servicing 27 ASCs in 7 states and performing ~185,000 procedures annually (at March 31, 2017)

## Strong Financial Performance Revenue & Adjusted Operating EBITDA<sup>(1)</sup>



<sup>(1)</sup>Total Operating EBITDA is a non-IFRS measure defined as operating income before interest, taxes, depreciation, and related expenses, amortization, stock-based compensation, acquisition-related expenses, and asset impairment charges. Refer to the end of the Company's Financial Report for the three months ended March 31, 2017, for a reconciliation of reported financial results to non-IFRS measures.

### WHY INVEST IN CRH

- ✓ Strong relationships with GI community built through O'Regan System's direct-to-physician model
- ✓ Scalable GI anesthesia national growth strategy. Approximately 800 - 1,000 GI-focused ASCs in the US
- ✓ Leveraging large pool of GI anesthesia acquisition targets
- ✓ Cash flow positive since 2008 and generating approximately \$6M in quarterly cash flow to fund organically-driven acquisition growth
- ✓ Credit facility provides additional financial capacity to invest in anesthesia growth at low interest rate

### EXECUTIVE MANAGEMENT

**Edward Wright – CEO** – Established CRH's direct-to-physician model to introduce the O'Regan system to the GI community. Leveraged CRH's excellent relationships to launch CRH Anesthesia. Over 10 years experience in health care.

**Richard Bear – CFO** – Has planned and executed all of CRH's financial transactions, including capital private placements debt facilities and all of CRH Anesthesia's transactions.

**Richard Bear – CFO** – Formerly VP of Development for the ASC division of HCA. Extensive experience in business development and operations.

### BOARD OF DIRECTORS

**Tony Holler, Chairman**  
**David Johnston, Independent**  
**Todd Patrick, Independent**  
**Ian Webb, Independent**  
**Edward Wright, CEO**

**Legal Disclaimer:** This document refers to some non-IFRS financial measures as supplemental indicators of our financial and operating performance. These non-IFRS measures include Operating EBITDA. The Company believes that supplementary indicators reflect the Company's ongoing business in a manner that allows for meaningful period-to-period comparisons and analysis of trends in its business. Please refer to the Company's report for the three months ended March 31, 2017 available at <http://investors.crhssystem.com/> for a reconciliation of these non-IFRS measures. This document may contain forward-looking statements that may involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance or achievements to differ materially from the future results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements reflect current expectations of management regarding future events and operating performance as of the date of this document. The Company bases its forward-looking statements on information currently available to it and assumes no obligation to update them, other than as required by law. Please refer to the Company's latest Financial Report and Annual Information Form, available on SEDAR at [www.sedar.com](http://www.sedar.com) and our website at <http://investors.crhssystem.com/> for a list of risks related to our business.